Inflation, expensive specialty drugs and demand for pricey glucagon-like peptide 1 medications, or GLP-1s, are pushing costs higher, according to the professional services company.
Inflation, expensive specialty drugs and demand for pricey glucagon-like peptide 1 medications, or GLP-1s, are pushing costs higher, according to the professional services company.